...
【24h】

Poster Exhibit 4: Infections

机译:海报图表4:感染

获取原文
           

摘要

Introduction: The impact of the COVID-19 pandemic on the management of metastatic hormone-sensitive prostate cancer (mHSPC) is unknown. Recent Canadian recommendations favor the use of androgen-receptor-axis targeted therapies (ARATs) over docetaxel to minimize risk of COVID-19 infections. We aimed to characterize how the pandemic has influenced current practice patterns of medical oncologists in Canada who treat mHSPC. Methods: Using SurveyMonkey?, we conducted an online survey among 119 practicing members of the Genitourinary Medical Oncologists of Canada (GUMOC) in January 2021. The survey consisted of 16 questions, including demographics, treatment approach before and during the pandemic, and outcomes of any COVID-19-positive patients with mHSPC. Results: Response rate was 42% (n=50). Most respondents were male (65%) and practiced in academic centers (71%). The majority (64%) described a change in practice patterns during the pandemic. For low- (LV) and high-volume (HV) mHSPC, the proportion of respondents offering ARATs increased from 73% to 79% and from 63% to 84%, respectively. Increased use of granulocyte colony-stimulating factor primary prophylaxis with docetaxel was reported by 35% of respondents, with 22% offering it to more than half of the patients on chemotherapy. Roughly half (45%) intend to maintain these practice changes beyond the pandemic. Only nine (18%) reported having mHSPC patients diagnosed with COVID-19, all of which were diagnosed prior to initiation of systemic therapy. Among these patients, 77% were treated with ARAT, none with docetaxel; four required hospitalizations (one required ICU), and all recovered. Conclusions: During the pandemic, Canadian medical oncologists reported using more ARATs and less docetaxel for patients with mHSPC. Many plan to maintain these changes post-pandemic. Further research is warranted to examine whether these practice changes impact outcomes. Encouragingly, no deaths related to COVID-19 among patients with mHSPC have been reported.
机译:简介:Covid-19大流行对转移激素敏感前列腺癌(MHSPC)的影响是未知的。最近的加拿大建议赞成使用雄激素受体轴针对性疗法(ARATS),以最大限度地减少Covid-19感染的风险。我们的旨在表征大流行如何影响加拿大治疗MHSPC的医疗肿瘤学家的现行实践模式。方法:使用Surveymonkey?,我们在2021年1月在加拿大泌尿生殖医学肿瘤学家的119名练习成员中进行了在线调查。该调查包括16个问题,包括在大流行前后的人口统计学,治疗方法以及结果任何Covid-19阳性MHSPC患者。结果:响应率为42%(n = 50)。大多数受访者是男性(65%),在学术中心练习(71%)。大多数(64%)描述了大流行期间实践模式的变化。对于低(LV)和大容量(HV)MHSPC,提供ARATS的受访者的比例分别从73%增加到79%,分别为63%至84%。增加了使用多西紫杉醇的粒细胞菌落刺激因子初前预防的使用增加了35%的受访者,其中22%以上的化疗患者提供了超过一半的患者。大约一半(45%)打算维持这些实践的变化超出大流行。仅报告患有Covid-19的MHSPC患者只有九(18%),所有这些都被诊断为启动全身治疗之前诊断出来。在这些患者中,77%用ARAT治疗,没有多西紫杉醇;四个所需住院(需要一个ICU),并全部康复。结论:在大流行期间,加拿大医疗肿瘤学家报告使用MHSPC患者使用更多阿拉特和少Docetaxel。许多计划在大流行后保持这些变化。有权进一步研究,以检查这些做法是否会发生影响结果。令人鼓舞的是,报告了MHSPC患者中与Covid-19相关的死亡。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号